What Is Wave Life Sciences Ltd. (WVE) Worth in 2026?
According to the CirclFi Deep Alpha Valuation Engine, Wave Life Sciences Ltd.'s intrinsic value is estimated at $3.80. Trading at its current price of $6.13, the valuation engine raises significant caution: 8 of 9 models flag downside risk, projecting an average implied return of -38.0%. Model dispersion is worth noting: PWERM targets $6.31 (+2.9%), versus ML-RIV at $0.39 (-93.6%). This +96.5% range highlights the importance of multi-model analysis rather than relying on any single methodology.
What Do the Models Say About WVE?
9 of 13 models are currently active for WVE. Of these, 1 model suggests upside while 8 models suggest overvaluation. The Bayesian DCF estimates WVE's intrinsic value at $3.24, implying -47.2% downside from the current price. See which stocks rank higher →
How Does WVE Rank in Pharmaceutical Preparations?
Among 469 Pharmaceutical Preparations stocks, WVE ranks #55 by Quality of Company score. CirclFi's QOC score of 7.3/10 evaluates 32 fundamental signals. A score of 7.3 indicates above-average quality.
See all Most Undervalued Pharmaceutical Preparations Stocks →
Wave Life Sciences Ltd.'s positioning within the Pharmaceutical Preparations segment means that FDA approval probability plays an outsized role in fundamental analysis. The sector's unique characteristics — including licensing and M&A optionality — shape both the opportunity set and risk profile.
Is WVE a Value Trap?
CirclFi's Value Trap algorithm assigns WVE a score of 30/100 (LOW). This indicates low risk. The financial profile does not exhibit typical value trap warning signs. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →
Multi-Model Methodology
9 of 13 models are active for Wave Life Sciences Ltd.. Moderate coverage provides meaningful perspective. Each model applies a fundamentally different valuation philosophy. See the complete methodology →
According to the CirclFi Deep Alpha Valuation Engine, Wave Life Sciences Ltd. scores 7.3 out of 10 on our 32-signal quality assessment, a solid rating that maintains reasonable quality metrics with some areas for improvement. The QOC score synthesizes profitability margins, revenue growth reliability, debt management, and capital allocation into a single metric designed to separate durable businesses from statistically cheap ones.
The gap between the most bullish and bearish model spans +96.5% — demonstrating why single-model analysis is dangerous. Browse all stocks with 13-model coverage →
Data Sources & Confidence
Every WVE valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →
Across WVE's 9 active models, average confidence is 24%. Lower confidence may reflect limited history or high volatility.
CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →
Buy with Gumroad